We prospectively investigated the short-term effects of intravenous methyl-prednisolone (IVMP) on cerebral volume in patients suffering a multiple sclerosis (MS) relapse. Ten patients underwent MRI brain studies immediately before and after IVMP treatment, and 4 and 8 weeks later. Whole brain volumes decreased significantly over the 8-week period. The greatest change occurred during IVMP administration. This has implications for MS treatment trials using cerebral atrophy as an endpoint. © 2006 Elsevier Ltd. All rights reserved
Multiple sclerosis (MS) is a chronic inflammatory demyelinating and degenerative disorder of the cen...
Introduction: The MRI evidence of persistent black holes (pBHs) on T1-weighted images reflects brain...
BACKGROUND AND PURPOSE: Evidence is needed to understand the effect of fingolimod on slowing down br...
We investigated the effect of oral and intravenous methylprednisolone treatment on subsequent relaps...
Objective - To investigate the efficacy of two different high doses of intravenous methylprednisolon...
Brain atrophy occurs at a faster rate in patients with multiple sclerosis (MS) than in healthy indiv...
Multiple sclerosis (MS) is a chronic disease with an inflammatory and neurodegenerative pathology. A...
Multiple sclerosis (MS) is a chronic disease with an inflammatory and neurodegenerative pathology. A...
Background: Glucocorticoid treatment is recommended as the first-line treatment of MS relapses, howe...
Background: Brain volume loss occurs in patients with relapsingremitting MS. Fingolimod reduced brai...
Introduction: Relapses of multiple sclerosis (MS) are usually treated with high-dose intravenous met...
OBJECTIVE: To compare the effects of intravenous methylprednisolone (IVMP) in patients with relapsin...
OBJECTIVE: To describe the dynamics of brain volume loss (BVL) at different stages of relapsing-remi...
The aim of the present meta-analysis was to evaluate the effect of disease-modifying drugs (DMD) on ...
Abstract Background Brain volume atrophy is observed in relapsing–remitting multiple sclerosis (RRMS...
Multiple sclerosis (MS) is a chronic inflammatory demyelinating and degenerative disorder of the cen...
Introduction: The MRI evidence of persistent black holes (pBHs) on T1-weighted images reflects brain...
BACKGROUND AND PURPOSE: Evidence is needed to understand the effect of fingolimod on slowing down br...
We investigated the effect of oral and intravenous methylprednisolone treatment on subsequent relaps...
Objective - To investigate the efficacy of two different high doses of intravenous methylprednisolon...
Brain atrophy occurs at a faster rate in patients with multiple sclerosis (MS) than in healthy indiv...
Multiple sclerosis (MS) is a chronic disease with an inflammatory and neurodegenerative pathology. A...
Multiple sclerosis (MS) is a chronic disease with an inflammatory and neurodegenerative pathology. A...
Background: Glucocorticoid treatment is recommended as the first-line treatment of MS relapses, howe...
Background: Brain volume loss occurs in patients with relapsingremitting MS. Fingolimod reduced brai...
Introduction: Relapses of multiple sclerosis (MS) are usually treated with high-dose intravenous met...
OBJECTIVE: To compare the effects of intravenous methylprednisolone (IVMP) in patients with relapsin...
OBJECTIVE: To describe the dynamics of brain volume loss (BVL) at different stages of relapsing-remi...
The aim of the present meta-analysis was to evaluate the effect of disease-modifying drugs (DMD) on ...
Abstract Background Brain volume atrophy is observed in relapsing–remitting multiple sclerosis (RRMS...
Multiple sclerosis (MS) is a chronic inflammatory demyelinating and degenerative disorder of the cen...
Introduction: The MRI evidence of persistent black holes (pBHs) on T1-weighted images reflects brain...
BACKGROUND AND PURPOSE: Evidence is needed to understand the effect of fingolimod on slowing down br...